Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:IDRA

Idera Pharmaceuticals (IDRA) Stock Price, News & Analysis

Idera Pharmaceuticals logo

About Idera Pharmaceuticals Stock (NASDAQ:IDRA)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.17
$7.23
52-Week Range
N/A
Volume
21,870 shs
Average Volume
464,030 shs
Market Capitalization
$450.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Aceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.

Receive IDRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Idera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IDRA Stock News Headlines

Ekso Bionics (NASDAQ: EKSO)
Vladimir Lenin was right…
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
Kiniksa Pharmaceuticals
Nabriva Therapeutics AG (NBRVF)
Marginalia
See More Headlines

IDRA Stock Analysis - Frequently Asked Questions

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) announced its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01.

Idera Pharmaceuticals shares split on the morning of Friday, November 25th 2022. The 2-1 split was announced on Friday, November 25th 2022. The newly minted shares were issued to shareholders after the closing bell on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Idera Pharmaceuticals investors own include BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Sorrento Therapeutics (SRNE), Proteostasis Therapeutics (PTI), Dynavax Technologies (DVAX), Agenus (AGEN) and SCYNEXIS (SCYX).

Company Calendar

Last Earnings
11/08/2021
Today
5/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:IDRA
Employees
32
Year Founded
1989

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$98.09 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
0.29
Book Value
$0.56 per share
Price / Book
N/A

Miscellaneous

Free Float
59,206,000
Market Cap
$450.52 million
Optionable
Optionable
Beta
1.25

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:IDRA) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners